Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.
A US Food and Drug Administration (FDA) advisory panel voted unanimously today to recommend a booster dose of Pfizer’s mRNA COVID-19 vaccine for those 65 and older and those at high risk for severe outcomes from the disease.
This followed an earlier 16-2 vote by the panel rejecting a booster dose for Americans age 16 and over.
The first vote was a rejection of Pfizer’s initial request for its Comirnaty vaccine, which was for the FDA to amend its approval for the vaccine to allow all Americans over the age of 16 to get a booster dose at least 6 months after their second dose.
It was also a rebuff to the Biden administration, which had prematurely announced that boosters would be rolled out to the general public by September 20.
This is a developing story.
Follow Medscape on Facebook, Twitter, Instagram, and YouTube.
Source: Read Full Article